Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ballard

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 2, 2011
Correction for nonspecific binding to various components of ultrafiltration apparatus and impact on estimating in vivo rat clearance for a congeneric series of 5-ethyl, 5-n-alkyl barbituric acidsPeter Ballard, Malcolm Rowland
Pharmaceutical Research|June 24, 2003
Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acidsPeter Ballard, David E Leahy, Malcolm Rowland
Journal of the American College of Emergency Physicians Open|February 28, 2023
A unique soft tissue injury with devastating delayed consequences: A video case reportKay Nicole Tipton, Jody Lakey, Peter Ballard, et al.
Pharmaceutical Research|June 24, 2003
Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (Kpu)Peter Ballard, Philip A Arundel, David E Leahy, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 23, 2018
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug LabelVenkatesh Pilla Reddy, Michael Walker, Pradeep Sharma, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 10, 2014
Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and manPeter Ballard, Helen C Swaisland, Michael D Malone, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 27, 2016
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor ReceptorPaul A Dickinson, Mireille V Cantarini, Jo Collier, et al.
Molecular Cancer Therapeutics|July 22, 2016
Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104James W T Yates, Susan Ashton, Darren Cross, et al.
Drug Metabolism Reviews|June 16, 2012
The right compound in the right assay at the right time: an integrated discovery DMPK strategyPeter Ballard, Patrick Brassil, Khanh H Bui, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitorsRichard Ducray, Peter Ballard, Bernard C Barlaam, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 2, 2011
Correction for nonspecific binding to various components of ultrafiltration apparatus and impact on estimating in vivo rat clearance for a congeneric series of 5-ethyl, 5-n-alkyl barbituric acidsPeter Ballard, Malcolm Rowland
Pharmaceutical Research|June 24, 2003
Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acidsPeter Ballard, David E Leahy, Malcolm Rowland
Journal of the American College of Emergency Physicians Open|February 28, 2023
A unique soft tissue injury with devastating delayed consequences: A video case reportKay Nicole Tipton, Jody Lakey, Peter Ballard, et al.
Pharmaceutical Research|June 24, 2003
Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (Kpu)Peter Ballard, Philip A Arundel, David E Leahy, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 23, 2018
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug LabelVenkatesh Pilla Reddy, Michael Walker, Pradeep Sharma, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 10, 2014
Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and manPeter Ballard, Helen C Swaisland, Michael D Malone, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 27, 2016
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor ReceptorPaul A Dickinson, Mireille V Cantarini, Jo Collier, et al.
Molecular Cancer Therapeutics|July 22, 2016
Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104James W T Yates, Susan Ashton, Darren Cross, et al.
Drug Metabolism Reviews|June 16, 2012
The right compound in the right assay at the right time: an integrated discovery DMPK strategyPeter Ballard, Patrick Brassil, Khanh H Bui, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitorsRichard Ducray, Peter Ballard, Bernard C Barlaam, et al.
Pageof 3